India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices

 
• By Anju Ghangurde

ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.

ImmunoACT hopes to provide affordable access to CAR-T cell therapy • Source: Shutterstock

More from India

More from Focus On Asia